Pelthos Therapeutics Inc. (PTHS) is a publicly traded Healthcare sector company. As of September 20, 2026, PTHS trades at $22.66 with a market cap of $86.71M and a P/E ratio of -0.98. PTHS moved +1.21% today. Year to date, PTHS is -16.73%; over the trailing twelve months it is -29.26%. Its 52-week range spans $13.76 to $54.29. Analyst consensus is strong buy with an average price target of $53.40. Rallies surfaces PTHS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
5 analysts cover PTHS: 0 strong buy, 5 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $53.40.
| Metric | Value |
|---|---|
| Price | $22.66 |
| Market Cap | $86.71M |
| P/E Ratio | -0.98 |
| EPS | $-23.04 |
| Dividend Yield | 0.00% |
| 52-Week High | $54.29 |
| 52-Week Low | $13.76 |
| Volume | 27.84K |
| Avg Volume | 0 |
| Revenue (TTM) | $16.80M |
| Net Income | $-43.32M |
| Gross Margin | 76.25% |
5 analysts cover PTHS: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $53.40.